Santos Cynthia, Olmedo Ruben E, Kim Jeremy
Department of Emergency Medicine, Emory University Hospital, Atlanta, GA.
Director, Division of Toxicology, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Emerg Med Pract. 2017 Mar 22;19(3 Suppl Points & Pearls):S1-S2.
Sedative-hypnotic drugs include gamma-Aminobutyric acid (GABA)ergic agents such as benzodiazepines, barbiturates, gamma-Hydroxybutyric acid [GHB], gamma-Butyrolactone [GBL], baclofen, and ethanol. Chronic use of these substances can cause tolerance, and abrupt cessation or a reduction in the quantity of the drug can precipitate a life-threatening withdrawal syndrome. Benzodiazepines, phenobarbital, propofol, and other GABA agonists or analogues can effectively control symptoms of withdrawal from GABAergic agents. Managing withdrawal symptoms requires a patient-specific approach that takes into account the physiologic pathways of the particular drugs used as well as the patient's age and comorbidities. Adjunctive therapies include alpha agonists, beta blockers, anticonvulsants, and antipsychotics. Newer pharmacological therapies offer promise in managing withdrawal symptoms. [Points & Pearls is a digest of Emergency Medicine Practice].
镇静催眠药物包括γ-氨基丁酸(GABA)能药物,如苯二氮䓬类、巴比妥类、γ-羟基丁酸[GHB]、γ-丁内酯[GBL]、巴氯芬和乙醇。长期使用这些物质会导致耐受性,突然停药或减少药物用量可能会引发危及生命的戒断综合征。苯二氮䓬类、苯巴比妥、丙泊酚和其他GABA激动剂或类似物可有效控制GABA能药物戒断症状。管理戒断症状需要采用针对患者的方法,该方法要考虑到所使用特定药物的生理途径以及患者的年龄和合并症。辅助治疗包括α激动剂、β阻滞剂、抗惊厥药和抗精神病药。新型药物疗法在管理戒断症状方面有前景。[要点与精华是《急诊医学实践》的摘要]